Search

Displaying results 4381 - 4390 of 5300 in total
  1. Drug

    Tovinontrine

    go.drugbank.com/drugs/DB16193
    Investigational

    Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.

  2. Drug

    Famprofazone

    go.drugbank.com/drugs/DB16702
    Experimental

    [L34724] It is important to note that the drug is metabolized to [methamphetamine] and [amphetamine] in the body and can lead to positive tests results for illicit drug use.

  3. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  4. Drug

    Lemzoparlimab

    go.drugbank.com/drugs/DB17572
    Investigational

    Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Partic...

  5. Drug

    Zodasiran

    go.drugbank.com/drugs/DB17626
    Investigational

    It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).[L45869]

  6. Drug

    AVR-RD-04

    go.drugbank.com/drugs/DB18644
    Experimental

    AVR-RD-04 is an investigational gene therapy for cystinosis.

  7. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa formulations can be administered intravenously or subcutaneously.

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML
  8. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    Due to its pharmacological properties, it can be administered intranasally.

  9. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  10. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; h...